Expert Interview
Examining the Phase 3 STELLAR-303 Results for Zanzalintinib plus Atezolizumab in Metastatic Colorectal Cancer
Ticker(s): EXELA gastrointestinal medical oncologist specializing in metastatic colorectal cancer, experienced with later-line therapies and immunotherapy-TKI combinations. The expert should be familiar with VEGF- and MET-pathway biology, subgroup differences such as liver metastasis status, and practical considerations when sequencing regorafenib and other target-based regimens. Experience interpreting survival-endpoint–driven Phase 3 data and understanding toxicity trade-offs for kinase inhibitor–immunotherapy combinations is preferred.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
